Drug Profile


Alternative Names: Autologous CD34+ cells - Caladrius; CLBS-12

Latest Information Update: 05 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Caladrius Biosciences
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Peripheral ischaemia

Highest Development Phases

  • Phase II Peripheral ischaemia

Most Recent Events

  • 01 Oct 2017 Phase-II clinical trials in Peripheral ischaemia in Japan (IM) (JapicCTI-173750) (NCT02501018)
  • 18 Apr 2016 CLBS 12 is available for licensing as of 18 Apr 2016.
  • 18 Apr 2016 Caladrius Biosciences announces that Japanese PMDA thirty-day review period passed without any comments from PMDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top